James P. Reilly Jr. was named president and chief operatingofficer of Ecogen Inc. He was vice president and generalmanager for fine organic chemicals at Rhone-Poulenc Inc.Ecogen (NASDAQ:EECN) of Langhorne, Pa., is an agriculturalbiotechnology company.
Martin Barkin was named president and chief operating officerand appointed to the board of Deprenyl Research Ltd. Hesucceeds James P. Doherty, who was named vice chairman andwill be a special adviser to the president. Barkin was a partnerand national practice leader for health care for Peat MarwickStevenson and Kellogg. Deprenyl Research (NASDAQ:DEPLF) ofToronto is developing products for Parkinson's and otherneurological diseases and disorders of aging.
Vertex Pharmaceuticals Inc. named Richard Aldrich chiefbusiness officer and Keith Ehrlich treasurer. Aldrich was vicepresident of business development and marketing. Ehrlich willcontinue to serve as director of finance. The Cambridge, Mass.,company (NASDAQ:VRTX) is focused on structure-basedrational drug design.
Leon Gauci was named executive vice president of U.S.operations and a director of Cortecs Ltd. He was associate vicepresident of clinical research for Hoffmann La-Roche. Cortecs ofMiddlesex, England, specializes in the discovery anddevelopment of drug delivery systems.
Calgene Inc. named Michael J. Motroni vice president offinance. He was corporate controller and chief accountingofficer. Daniel O. Wagster II, formerly chief financial officer,was named vice president of operations and chief financialofficer for Calgene Fresh Inc., a wholly owned subsidiary. Davis,Calif.-based Calgene (NASDAQ:CGNE) develops geneticallyengineered plants and plant products.
Janet C. Bush has resigned as vice president of finance andadministration of ImmuLogic Pharmaceutical Corp. to pursueother interests, the company said. The Cambridge, Mass.,company (NASDAQ:IMUL) is developing products to treatallergies and autoimmune diseases.
OraVax Inc. named Robert B. Rombauer vice president ofbusiness development. He was vice president and partner ofMerrill Lynch Venture Capital. Privately held OraVax ofCambridge, Mass., is focused on the prevention and treatmentof human infectious diseases.
(c) 1997 American Health Consultants. All rights reserved.